Giovanni Grignani, MD

home / authors / giovanni-grignani-md

Articles

Dr. Grignani on the Patient Population of Trabectedin for Sarcoma

Dr. Grignani on the Patient Population of Trabectedin for Sarcoma

Giovanni Grignani, MD
June 23rd 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

Read More

Dr. Grignani on the Future of Treatments for Sarcoma

Dr. Grignani on the Future of Treatments for Sarcoma

Giovanni Grignani, MD
June 8th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the future of treatments for patients with soft tissue sarcoma.

Read More

Dr. Grignani Discusses the Safety Profile of Trabectedin in Sarcoma

Dr. Grignani Discusses the Safety Profile of Trabectedin in Sarcoma

Giovanni Grignani, MD
March 10th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the safety profile of trabectedin (Yondelis) in the treatment of sarcoma.

Read More

Dr. Grignani on the Role of Trabectedin in Sarcoma

Dr. Grignani on the Role of Trabectedin in Sarcoma

Giovanni Grignani, MD
February 4th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses some of the data seen thus far with trabectedin as a treatment for patients with sarcoma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data